Darbepoetin Alfa (Aranesp)

Covers darbepoetin alfa (Aranesp) for anemia of chronic kidney disease in patients on or not on dialysis per the FDA-approved indication and excludes non–FDA-approved uses (including oncology-related anemia). Approvals require meeting age-specific hemoglobin thresholds for initial and continuation therapy (adults: initial Hgb <10.0 g/dL, continuation <11.5 g/dL; pediatrics: initial ≤11 g/dL, continuation ≤12 g/dL), documentation of iron therapy or adequate iron stores, weight- and dialysis-status–based per-dose mcg/kg and frequency limits, and are authorized for up to 12 months.

"Anemia associated with chronic kidney disease (CKD) in individuals on dialysis and individuals not on dialysis."

Sign up to see full coverage criteria, indications, and limitations.